publication . Article . Other literature type . 2016

Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers

Morrison Joly, M.; Hicks, D. J.; Jones, B.; Sanchez, V.; Estrada, M. V.; Young, C.; Williams, M.; Rexer, B. N.; Sarbassov, D. D.; Muller, W. J.; ...
Open Access
  • Published: 25 Apr 2016 Journal: Cancer Research, volume 76, pages 4,752-4,764 (issn: 0008-5472, eissn: 1538-7445, Copyright policy)
  • Publisher: American Association for Cancer Research (AACR)
Abstract
HER2 overexpression drives Akt signaling and cell survival and HER2-enriched breast tumors have a poor outcome when Akt is upregulated. Akt is activated by phosphorylation at T308 via PI3K and S473 via mTORC2. The importance of PI3K-activated Akt signaling is well documented in HER2-amplified breast cancer models, but the significance of mTORC2-activated Akt signaling in this setting remains uncertain. We report here that the mTORC2 obligate cofactor Rictor is enriched in HER2-amplified samples, correlating with increased phosphorylation at S473 on Akt. In invasive breast cancer specimens, Rictor expression was upregulated significantly compared with nonmalignan...
Subjects
Medical Subject Headings: skin and connective tissue diseases
free text keywords: mTORC2, Lapatinib, medicine.drug, medicine, Breast cancer, medicine.disease, mTORC1, Cancer research, Immunology, Tumor progression, PI3K/AKT/mTOR pathway, Protein kinase B, business.industry, business, Cancer, Article
Related Organizations
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . Other literature type . 2016

Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers

Morrison Joly, M.; Hicks, D. J.; Jones, B.; Sanchez, V.; Estrada, M. V.; Young, C.; Williams, M.; Rexer, B. N.; Sarbassov, D. D.; Muller, W. J.; ...